| Net income | -80.2M |
| Gain on sale of assets | |
| Deferred income taxes | 3.69M |
| Impairments | |
| Depreciation, depletion and amortization | 112.41M |
| Debt issuance cost and discount amortization | 6.41M |
| Stock-based compensation | 3.57M |
| Excess income taxes from stock-based compensation | |
| Increase in accounts receivable | 101K |
| (Increase) decrease in other current assets | 18K |
| Increase (decrease) in accounts payable and accrued expenses | -37.44M |
| Net cash provided by operating activities | |
| Capital expenditures | -41.14M |
| Proceeds from asset sales | |
| Net cash used for investing activities | |
| Borrowings | 0 |
| Principal payments on debt | -3.39M |
| Debt issuance costs | |
| Proceeds from issuance of common stock | |
| Excess income taxes from stock-based compensation | |
| Net cash provided by (used for) financing activities | |
| Net increase (decrease) in cash and cash equivalents | -107.42M |
| Cash and cash equivalents, beginning of period | 134.01M |
| Cash and cash equivalents, end of period | 26.58M |